Author: Customer Service

VANCOUVER, BC, April 10, 2026 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: DGTEF) (FSE: 9880) (“DATT” or the “Company”), a technology focused investment issuer, announces that, in connection with a continuous disclosure review by the British Columbia Securities Commission (the “BCSC”), the Company intends to amend and refile certain previously filed financial statements and related management’s discussion and analysis (“MD&A”). The Company has determined that its previously filed:audited annual financial statements and MD&A for the year ended July 31, 2025; and  interim financial statements and MD&A for subsequent periods contain disclosure and accounting errors relating primarily to:the accounting treatment and valuation of the Company’s acquisition of LiquidLink AI Corp.;  the accounting...

VANCOUVER, BC, April 10, 2026 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: DGTEF) (FSE: 988) (“DATT” or the “Company”), a technology focused investment issuer, is issuing this news release at the request of the British Columbia Securities Commission (the “BCSC”) to provide supplemental, corrective and clarifying information regarding its news releases dated June 30, 2025 and May 7, 2025, including its material change report dated May 7, 2025 (collectively, the “Prior Disclosure”). Retraction of Prior Disclosure The Company retracts certain disclosure in the Prior Disclosure relating to the LiquidLink AI Corp. business. The retracted disclosure includes statements regarding:The acquisition enables the company to acquire Ripple (XRP) and LiquidLink is developing Xrpfy that enables users to search for tokenized...

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Sandisk Corporation (Nasdaq: SNDK) will become a component of the Nasdaq-100 Index® (NDX®) replacing Atlassian Corporation (Nasdaq: TEAM) prior to market open on Monday, April 20, 2026. These updates are consistent with the current Nasdaq-100 Index® methodology, in effect through April 30, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world’s leading index providers, offering a comprehensive suite of rules-based benchmarks and indexes. The Nasdaq-100 Index® — which measures the performance of 100 of the largest Nasdaq-listed non-financial companies — is tracked by more than 200 investment...

GREELEY, Colorado, April 10, 2026 (GLOBE NEWSWIRE) — Pilgrim’s Pride Corporation (NASDAQ: PPC) (the “Company”) announced today the early tender results for its cash tender offer (the “Tender Offer”) for up to $250 million aggregate principal amount (the “Maximum Tender Amount”) of its 6.250% Senior Notes due 2033 (the “Notes”). The Company has been advised that as of 5:00 p.m., New York City time, on April 10, 2026 (such date and time, the “Early Tender Date”), $471,546,000 aggregate principal amount of Notes had been validly tendered and not validly withdrawn in the Tender Offer. Withdrawal rights for the Notes expired on the Early Tender Date. The Tender Offer is being made upon the terms, and subject to the conditions, previously described in the offer to purchase dated March 30, 2026 (the “Offer to Purchase”). The Company refers...

MIAMI, April 10, 2026 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, announces the initial closing of the transfer of its Virginia operations into Arboretum Virginia LLC, a wholly-owned subsidiary of Arboretum Bidco LLC (“Arboretum”), and the closing and initial funding of its new money exit facility (the “Exit Facility”) with Arboretum, in connection with the Company’s previously announced restructuring transactions (the “Restructuring Transactions”). Arboretum, which intends to operate under the trade name “Ayr Wellness,” is the entity established by the Company’s senior secured noteholders as the designated purchaser under the Master Purchase Agreement, dated November 14, 2025 (the “MPA”). Additional state-level operations...

Not for distribution to United States Newswire Services or for dissemination in the United States VANCOUVER, British Columbia, April 10, 2026 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX- V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce that it has closed a non-brokered private placement offering of 1,110,000 national flow-through shares in the capital of Brixton (“FT Shares”) at a price of $1.35 per FT Share and 1,771,111 critical mineral flow-through shares in the capital of Brixton (the “CMFT Shares”) at a price of $1.44 per CMFT Share, for combined gross proceeds of $4,048,899.84 (the “Offering”). The gross proceeds from the sale of FT Shares will be used to incur “Canadian exploration expenses” and “flow-through mining expenditures” as defined in the Income Tax Act (Canada) (the “Act”). The gross...

TORONTO, April 10, 2026 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd. (TSXV: QGR; OTCQB: QGLDF; Börse Frankfurt: QX9G) (“QGold” or the “Company”) is pleased to announce that it will be hosting a corporate update presentation with analysts and investors via live webinar on Tuesday, April 14, 2026, at 11:00 a.m. (Toronto time). Participants can register to attend at the following web address: https://us06web.zoom.us/meeting/register/0710C4SnTUWTxff5soUKkg. Specifically, the webinar will feature QGold’s Chief Executive Officer and Executive Chairman, Peter Tagliamonte, to discuss the preliminary results from the Company’s anticipated preliminary economic assessment. About Q-Gold Resources Ltd. Q-Gold Resources Ltd. (TSXV: QGR; OTCQB: QGLDF; Börse Frankfurt: QX9G) is a publicly traded North American-based mineral exploration and development...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, April 10, 2026 (GLOBE NEWSWIRE) — Consolidated Lithium Metals Inc. (TSXV: CLM | FRA: Z36 | OTCQB: JORFF) (“CLM” or the “Company”) is pleased to announce that, further to its press release on March 18, 2026, it has closed the second and final tranche (the “Final Tranche”) of its previously announced non-brokered offering (the “Offering”) of securities of the Company. Together with the first tranche of the Offering, the Company obtained gross proceeds of approximately $8,935,320. In connection with the Final Tranche, the Company obtained aggregate gross proceeds of approximately $1,050,320 by issuing 10,940,830 flow-through shares of the Company (each, a “Critical FT Share”) at a price of $0.096 per Critical FT Share. Each Critical...

LUXEMBOURG, April 10, 2026 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced today that has convened its Annual General Meeting of Shareholders to be held on May 12, 2026, at 10:00 (Central European time), and an Extraordinary General Meeting of Shareholders to be held immediately after the adjournment of the Annual General Meeting of Shareholders. The convening notice (which includes the agendas for the meetings and the procedure for attending and/or voting at the meetings) was published in such newspapers and filed with the regulators, as required by applicable law, and is available on the Luxembourg Stock Exchange’s website at www.bourse.lu/regulated-information-oam, the SEC’s website at www.sec.gov, and Tenaris’s website at ir.tenaris.com. The following documents are also available on Tenaris’s...

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma. Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced cancer patients. In the IGNYTE trial, patients with confirmed progression on an anti-PD-1 based regimen who received RP1 plus nivolumab had a 34% response rate with a median duration of 24.8 months...